Tizanidine


Concise Prescribing Info
Indications/Uses
Spasticity in patient with multiple sclerosis or spinal cord injury or disease.
Dosage/Direction for Use
Adult: PO Initial: 2 mg as a single dose, increase according to patient's requirement and response in increments of 2-4 mg daily at 3-4 days interval. Dose should be taken in 3-4 divided doses. Usual dose: 24 mg/day. Max: 36 mg/day.
Contraindications
Concomitant use with potent CYP1A2 inhibitors (e.g. fluvoxamine, ciprofloxacin). Hepatic impairment.
Special Precautions
Patient with psychiatric disorder, CV disorder, coronary artery disease. Renal impairment. Elderly. Pregnancy and lactation. Avoid abrupt dose reduction and withdrawal. Patient Counselling This drug may cause drowsiness, dizziness, and hypotension, if affected, do not drive or operate machinery. Monitoring Parameters Monitor LFT at baseline and monthly for the first 4 months of therapy. Monitor blood pressure, renal function, and ECG periodically.
Adverse Reactions
Significant: Hepatotoxicity, hypersensitivity reactions, hypotension, sedation, hallucinations. Gastrointestinal disorders: Xerostomia. General disorders and administration site conditions: Weakness, fatigue, withdrawal hypertension. Infections and infestations: Infection. Investigations: Increased liver enzymes. Nervous system disorders: Dizziness, drowsiness. Cardiac disorders: Bradycardia, tachycardia.
Drug Interactions
Enhanced CNS effects with sedatives and other CNS depressants (e.g. benzodiazepines, opioids, TCA). Increased hypotensive effects, rebound hypertension and tachycardia with β-adrenoceptor blockers, digoxin. Increased plasma concentration with oral contraceptives.
CIMS Class
ATC Classification
M03BX02 - tizanidine ; Belongs to the class of other centrally-acting muscle relaxants.
Disclaimer: This information is independently developed by CIMS based on tizanidine from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 CIMS. All rights reserved. Powered by CIMSAsia.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in